Colibacillosis is an important disease in the poultry industry which causes serious economic damages. As it is suggested that vaccination is one of the means to control colibacillosis, we tried to investigate the vaccine potential of a aroA derivative of an O78:K80 avian pathogenic Escherichia coli containing increased serum survival gene. 490 chicks were selected as follows: For assessment of virulence of aroA mutant, 30 chicks were divided into three groups and injected with 0.5ml of PBS or bacterial suspension containing either10 7 colony forming units (CFU) of mutant or parent strains via subcutaneous route. Macroscopic lesions and mortality rate were recorded in different groups during the week after challenge. For assessment of safety and immunogenicity of the aroA mutant, three groups of 20 chicks were vaccinated by aerosol administration of 250 ml of suspension containing 10 8 CFU of mutant strain at days 1 and 14, while the two other groups received PBS or wild type strain. Macroscopic lesions and mortality rate were recorded in different groups until day 21. To determine whether the vaccination is protective against challenges or not, the chickens were vaccinated at days 1 and 14 and challenged intramuscularly with either a homologous or heterologous strains at day 21. Macroscopic lesions and mortality rate were recorded in different groups during the week after challenge. The results revealed that the aroA mutant was slightly virulent, however it was safe and did not cause mortality, lesions or weight loss after vaccination. Antibody responses were similar in the control and mutant groups and vaccination did not induce a significant humoral immunity. The mutant could not protect chickens against both homologous and heterologous challenges. This could be due to several factors such as the high amount of maternal antibodies in the first two weeks of life, and the vaccination procedure.
INTRODUCTION
Colibacillosis is one of the most important diseases of the poultry industry around the world. It causes considerable economical damage every year, due directly to increased mortalities and indirectly because of reduced weight gain, increased feed conversion rate and carcass condemnation (30) .
A wide range of E. coli serogroups, including O2 and O78 which are among most frequent, have been isolated from poultry lesions due to colibacillosis (7, 10, 13, 30) .
It has been suggested that resistance to complementmediated lysis and opsonophagocytosis are key factors in avian pathogenic E. coli (APEC) virulence (22, 23, 32) . Iss is a plasmid-encoded outer membrane protein (OMP) which plays a subtle role in the resistance of APEC to serum (3, 19) . The iss gene occurs more frequently in APEC than in strains isolated from apparently healthy birds, and has been reported in different serotypes (18, 27, 29) . The strong association of Iss protein among different E. coli strains suggests that it could be a good antigen to control and detect APEC. In this case, Lynn et al. (17) have used recombinant Escherichia coli Iss protein for immunization of chickens against APEC. They showed that there were lower lesion scores in vaccinated chickens that had developed a humoral response to Iss, after both homologous and heterologous challenges in comparison to unimmunized birds. However, they placed emphasis on further investigations into the vaccine potential of Iss protein for protection against APEC.
Vaccination is one of the various methods which has been applied to control colibacillosis. Live, killed and subunit are different types of vaccines that have been used (14, 30) . The live vaccines would be considered the most appropriate for immunization against colibacillosis in view of the fact that their construction is more economical than subunit vaccines and they are also suitable for mass administration via drinking water or aerosol (26) . Moreover, in the production process of inactive vaccines, it is possible that antigenic determinants were changed or eliminated, while in live vaccines they will remain unchanged, which is essential for a proper immune response (15) . By the advent of genetically defined mutants the risk of reversion to wild-type strain, which is always a challenge for the production of live vaccines, was removed.
There has been some effort to construct genetically defined mutants of avian pathogenic E. coli (15, 16, 25) . Evidence in literature showed that antibody responses did not differ significantly in chickens vaccinated with cya crp mutants of either an O2 or an O78 APEC strain and control group.
Although, the mutant of O2 strain induced only moderate protection against air sac infection (26). Kariyawasam et al. (15) revealed that galE, purA and aroA mutants of an O78 APEC strain were safe and produced a stronger immune response in vaccinated chickens than in the control groups.
However, they only provided protection against homologous challenge and failed to protect against heterologous challenge.
The aim of present study was to evaluate the safety, immunogenicity and protective ability of an aroA mutant of an O78:K80 APEC containing the iss gene against avian colibacillosis in broilers. Resources (12) .
MATERIALS AND METHODS

Chickens
Bacterial strains
The mutant strain was constructed by deletion of the aroA gene from a wild type strain belonging to O78:K80 serotype (1). Finally, the exact amount of bacteria was determined by a surface plate bacterial count method. All media used in the current study were purchased from Merck, Germany.
Characterization of mutant strain
Mutant strain was cultured in minimal medium and aromatic-mix medium for confirmation of its phenotypic Gels were stained in a 0.5 g/ml ethidium bromide solution for 15 minutes and photographed by CCD Video Camera.
Assessment of attenuation of mutant strain
In this experiment, the attenuation of mutant was evaluated by infecting day old chickens as described previously (25) . 30 chickens were divided into three groups of 10 and injected with 0.5 ml of PBS or bacterial suspension containing either10 7 CFU/ml of mutant strain or 10 7 CFU/ml of wild type 1378 strain via subcutaneous route. Chickens were monitored every 6 hours for the first day and then every 12 hours until day 7. Mortalities were recorded and surviving chickens were euthanized at day 7. Macroscopic lesions were scored according to data from Peighambari et al. (26) . Samples were taken from bone marrow, blood, liver and air sacs and cultured on MacConkey agar.
Evaluation of immunogenicity and safety of mutant strain
In this experiment, three groups of 20 chickens were vaccinated by aerosol administration of 250 ml of suspension 
Assessment of protection against homologous challenge
To determine whether vaccination is protective against homologous challenge or not, the chickens were vaccinated at days 1 and 14. For this reason, 100 chickens were divided into five groups as follow: two groups of 26 chickens received 250 ml of suspension containing 10 8 CFU/ml of mutant or wild type 1378 strain by aerosol route and another group of 26 chickens were vaccinated orally by administration of one ml of 10 8 CFU/ml of mutant strain suspension. Two groups of 11chickens, one received PBS and the other received no treatment, were also considered as negative control groups. At day 21, the chickens were challenged with wild type 1378 strain intramuscularly (33) . The chickens were monitored daily for signs of illness and death and all chickens were weighed at days 1,7,14 and 21. Surviving chickens were euthanatized at day 28, macroscopic lesions were scored and bacterial culture was performed as described before. This experiment was done in duplicate.
Assessment of protection against heterologous challenge
The experiment was designed similarly to the protection study against homologous challenge, but a virulent E. coli strain, which belonged to O2:K12 serotype, was used for challenge. This experiment was done in duplicate. 
Statistical analysis
RESULTS
Characterization of mutant strain
In contrast to wild type 1378 strain, mutant strain had no growth in the minimal medium, but it was spread in the aromatic-mix medium. A 575 bp band corresponding to the deleted aroA gene was observed in the mutant strain ( Figure 1 ).
Attenuation of mutant strain
All chickens treated with wild type 1378 strain died during the 72 hours after inoculation with signs of acute colisepticemia such as dark and congested internal organs. In contrast, only one chicken was found dead in the mutant group, with progressive signs of air sacs infection, perihepatitis and pericarditis. The O78:K80 E. coli strain was recovered from the lesions of dead chickens. No mortality in the control group was recorded. Avian colibacillosis induced by an aroA mutant
Immunogenicity and safety of mutant strain
No mortalities were observed in the group which received the mutant strain or sterile solution of 0.9% w/v of NaCl, while eight chickens died in the group treated with wild type 1378 strain, and this difference was significant(P<0.05). In the case of macroscopic lesions, significant differences were found between the wild type group and either the mutant or control groups (P<0.05) ( Table 1 ). The results of rapid and tube agglutination tests showed that there was no significant difference in the antibody response between the mutant group and the control group (P> 0.05).
Protection against homologous challenge
No significant difference regarding mortality and macroscopic lesion scores was seen between the studied groups (P> 0.05). However, the groups which were vaccinated by mutant strain had significantly higher weight gain in comparison to the group treated with wild type 1378 strain (P<0.05) ( Table 2 ). Similar results were obtained for heterologous challenge. 
DISCUSSION
Mutation of certain auxotrophic genes such as aroA has been employed to construct attenuated strains of various bacteria including APEC, Salmonella typhimurium, Salmonella choleraesuis, Bordetella pertussis (11, 15, 21, 28) . In this study, we evaluated the attenuation, immunogenecity and protective ability of the aroA mutant from a native E. coli O78:
K80 strain in broilers. The results of the attenuation study revealed the safety of the mutant strain, as vaccination with mutant had no impact on mortalities and lesions, which is in agreement with previous data (15, 26) . The attenuation is due to the inability of aroA mutants to synthesize chorismic acid, which is an intermediate product of p-aminobenzoic acid, aromatic amino acids, and folate biosynthesis rather than indirect effects on the expression of virulence factors (28, 31) .
Additionally, the weight gain of the chickens during the first three weeks of life showed that there was no negative effect because of vaccination (Table 2) . Similarly, Panigrahy et al. In contrast to the findings of Kariyawasam et al. (15) , vaccination failed to protect chickens against homologous challenge and there were high mortalities in the vaccinated groups after the challenge. One possible explanation is that in the present study, a systemic route of challenge which has severe outcome regarding mortalities and lesions was used, but in that study an aerosol challenge was applied. In addition, in the current study droplets were delivered with a size of about 50 m, which was larger than those in the study of (15, 26) . In case of inability of oral vaccination to protect chickens, there is evidence that it is necessity to vaccinate chickens with 10 10 CFU/ml of bacteria (1, 8) .
The failure in protection against heterologous challenge was in accordance with previous studies (5, 15, 26) . This serogroup associated protection highlights the possible role of LPS as a crucial factor in immunization with live E. coli vaccine. Based on the results of the current study, further investigations on other serogroups of APEC may be required to determine whether live vaccine can be effective against avian colibacillosis or not.
